Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis

Diabetes Obes Metab. 2024 Mar;26(3):1129-1132. doi: 10.1111/dom.15396. Epub 2023 Dec 11.

Authors

Ofer Kobo¹, Matthew A Cavender², Thomas Jon Jensen³, Anja Birk Kuhlman³, Søren Rasmussen³, Subodh Verma⁴

Affiliations

¹ Hillel Yaffe Medical Centre, Hadera, Israel.
² University of North Carolina, Chapel Hill, North Carolina, USA.
³ Novo Nordisk A/S, Søborg, Denmark.
⁴ St. Michael's Hospital of Unity Health, Toronto, Canada.

PMID: 38082468
DOI: 10.1111/dom.15396

No abstract available

Publication types

Letter

MeSH terms

Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptides / adverse effects
Humans
Hypoglycemic Agents / adverse effects

Substances

semaglutide
Glucagon-Like Peptides
Hypoglycemic Agents

Grants and funding

Novo Nordisk A/S